Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped?

Archives of Disease in Childhood

Volumn 91, Issue 9, 2006, Pages 793-794

  Webb, E ^a   Viner, R ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ANAMNESIS; BEHAVIOR; BODY MASS; CASE REPORT; CLINICAL EXAMINATION; FEMALE; HUMAN; LABORATORY TEST; NOTE; NUTRITIONAL ASSESSMENT; OBESITY; PHYSICAL EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; CHILD; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; TREATMENT FAILURE;

EID: 33748457687     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.098962     Document Type: Note

References (18)

1. Bao W, Srinivasan SR, Wattigney WA, et al. Persistence of multiple cardiovascular disease risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med 1994;154:1842-7.
2. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001;50:2444-50.
3. Nelson MJ, Ragland DR, Syme SL. Longitudinal prediction of adult blood pressure from juvenile blood pressure levels. Am J Epidemiol 1992;136:633-45.
4. Webber LS, Srinivasan SR, Wattigney WA, et al. Tracking of serum lipids and lipoproteins from childhood to adolescence. Am J Epidemiol 1991;133:884-99.
5. Huang TT, Johnson MS, Figueroa-Colon R, et al. Growth of visceral fat, subcutaneous abdominal fat, and total body fat in children. Obes Res 2001;9:283-9.
6. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1998;37:1595-607.
7. Viner RW, Segal TY, Lichtarowicz-Krynska E, et al. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005;90:10-14.
8. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-7.
9. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylureo, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998;128:165-75.
10. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000;16:2-7.
11. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:920-6.
12. Knowler WC, Barred-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
13. Chou KH, von Eye CH, Capp E, et al. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003;35:86-91.
14. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
15. Kurukulasuriva R, Banerji MA, Chaiken R, et al. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes 1999;48:A315.
16. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-61.
17. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.
18. Grade of Recommendation, www.cebm.net.